The major symptom is increased pressure within the skull (increased intracranial pressure). There is no evidence of tumor, infection, blocked drainage of the fluid surrounding the brain, or any other cause.
Despite the increased pressure in the skull, there is no change in alertness.
Tests that may be done include:
CT Scan
MRI
Lumbar puncture (spinal tap)
Eye exam, including formal visual field testing
The diagnosis is made when other health conditions are ruled out. Several conditions may cause increased intracranial pressure, including venous sinus thrombosis, hydrocephalus, and an intracranial mass (such as a tumor).
Treatment
Treatment must be directed at the specific cause of the pseudotumor.
A lumbar puncture can help relieve pressure within the brain and prevent vision problems.
Other treatments may include:
Fluid or salt restrictions
Medications such as corticosteroids, glycerol, acetazolamide, and furosemide
Shunting procedures to relieve pressure due to spinal fluid retention
Surgery to relieve pressure on the optic nerve
Weight loss
The patient will need their vision closely monitored, since there is potential for progressive and sometimes permanent visual loss. Follow-up MRI or CT scans may be done to rule out hidden cancer.
Outlook (Prognosis)
Sometimes the condition disappears on its own within 6 months. About 10-20% of persons have their symptoms return. A small number of patients have symptoms that slowly get worse and lead to blindness.
Possible Complications
Vision loss is a serious complication of this condition.
When to Contact a Medical Professional
Call your health care provider if you or your child experience the symptoms listed above.
References
Jonnalagadda J. Lithium, minocycline, and pseudotumor cerebri. J Am Acad Child Adolesc Psychiatry. March 1, 2005; 44(3): 209.
Behrman RE. Nelson Textbook of Pediatrics. 17th ed. Philadelphia, Pa: WB Saunders; 2004; 2048-2049.
Review Date:
3/26/2009
Reviewed By:
David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; and Daniel B. Hoch, PhD, MD, Assistant Professor of Neurology, Harvard Medical School, Department of Neurology, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.